OAK

一行要約

プラチナ既治療の進行 NSCLC における Atezolizumab vs Docetaxel の phase III。OS HR 0.73 (13.8 vs 9.6 mo) で PD-L1 発現によらず生存改善を示し、PD-L1 発現非依存の 2L 免疫療法オプションとして承認された。

試験デザイン

• 対象: Stage IIIB/IV NSCLC、プラチナベース化学療法後の 2L 以降、PD-L1 発現不問、N=1225 (1:1)
• 介入群 (n=613) : Atezolizumab 1200mg IV q3w
• 対照群 (n=612) : Docetaxel 75mg/m² IV q3w
• 層別化: PD-L1 発現 (TC0/IC0 vs TC1-3/IC1-3)、化療レジメン数、組織型
• 特徴: PD-L1 発現を問わず登録した点で KEYNOTE-024 や CheckMate-227 と異なる inclusive なデザイン
• PD-L1 評価: SP142 assay (TC/IC scoring system) を使用

主要結果

• OS (primary) : HR 0.73 (95% CI 0.62–0.87, p=0.0003)、median 13.8 vs 9.6 mo
• PFS: HR 0.95 (95% CI 0.82–1.10)、有意差なし (median 2.8 vs 4.0 mo)
• ORR: 14% vs 13% (差軽微だが DoR は顕著に長い: 16.3 vs 6.2 mo)
• PD-L1 サブグループ: TC3/IC3 (高発現) で OS HR 0.41、TC0/IC0 (陰性) でも OS HR 0.75 と改善傾向
• 安全性: Grade 3-4 AE 15% vs 43%、治療中止率 8% vs 19%。Atezolizumab で irAE (肺臓炎・肝炎)、Docetaxel で骨髄抑制・感染症

臨床的意義

• PD-L1 陰性でも有効: KEYNOTE-010 (PD-L1 TPS≥1% 限定) と異なり、PD-L1 発現を問わず 2L で使用可能な IO として承認根拠
• 3 番目の 2L IO 承認: Nivolumab (CheckMate-227 系列)、Pembrolizumab に続く 3rd PD-(L)1 inhibitor の 2L 承認
• 抗 PD-L1 の差別化: PD-L1 直接阻害で PD-1/PD-L2 シグナルを温存する理論的差異が議論された
• 1L IO 時代への橋渡し: OAK の成功が IMpower150 (Atezolizumab + BCP) など 1L combination 試験の開発を加速

Open Questions

• OAK 時代の 2L IO は 1L IO 後にどう位置づけられるか: 1L KEYNOTE-189 / IMpower150 後の 2L では IO re-challenge の意義が不明確
• SP142 vs 22C3 vs 28-8 の PD-L1 assay 間 discordance: OAK の SP142 判定と他試験 assay の concordance は限定的
• bTMB の 2L IO biomarker としての実用性: OAK 副次解析で示唆されたが prospective validation は未完

重要論文 Top 10

1. ★★★★★ Rittmeyer et al. Lancet 2017 — OAK primary publication、OS HR 0.73
2. ★★★★★ Gandara et al. NatMed 2018 — OAK の blood-based TMB 解析、bTMB biomarker 開発
3. ★★★★ Fehrenbacher et al. Lancet 2016 — POPLAR phase II (OAK の先行試験)、PD-L1 enrichment 効果
4. ★★★★ Herbst et al. Lancet 2016 — KEYNOTE-010 (Pembrolizumab 2L) との比較文脈
5. Borghaei et al. — CheckMate-057 (Nivolumab 2L non-squamous) —OAK と並ぶ 2L IO 根拠

関連エンティティ・概念

• PD-L1-inhibitor — Atezolizumab (抗 PD-L1 抗体)
• PD-L1 — Biomarker (SP142 assay)
• Taxane — Docetaxel (対照群)
• IMpower150 — Atezolizumab 1L combination への発展
• IMpower133 — Atezolizumab の SCLC 展開
• irAE-pathophysiology — 免疫関連有害事象

関連論文

直近 30 件のみ表示中 (関連 62 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Eguren-Santamaria et al. ClinCancerRes 2020 — PD-1pd-L1 blockers in NSCLC brain metastases challenging paradigms and clinical practice
• Page et al. EurJCancer 2020 — Systemic treatment of brain metastases in non-small cell lung cancer

Basic-Immunotherapy

• Schoenfeld et al. CancerCell 2020 — Acquired resistance to immune checkpoint inhibitors
• Hakozaki et al. CancerImmunolRes 2020 — The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung
• Petralia et al. Cell 2024 — Pan-cancer proteogenomics characterization of tumor immunity
• Lopez-Janeiro et al. JClinInvest 2026 — Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
• Gonzalez-Kozlova et al. NatMed 2026 — Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade

Basic-Liquid-biopsy

• Kilgour et al. CancerCell 2020 — Liquid biopsy-based biomarkers of treatment response and resistance

Basic-Neutrophil and myeloid cell

• Salcher et al. CancerCell 2022 — High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell
• Benguigui et al. CancerCell 2024 — Interferon-stimulated neutrophils as a predictor of immunotherapy response

Basic-Oncogene and genetics

• Singh et al. ClinCancerRes 2021 — NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes

Clinical-Epidemiology

• Howlader et al. NEnglJMed 2020 — The effect of advances in lung-cancer treatment on population mortality

Clinical-NEC

• Tashiro et al. IntJMolSci 2020 — Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK
• Sherman et al. LungCancer 2020 — Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Clinical-NSCLC-Driver negative

• Amrein et al. CancerImmunolImmunother 2021 — Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC SAKK19-09 study
• Gadgeel et al. ClinLungCancer 2022 — Comparison of SP142 and 22c3 immunohistochemistry PD-L1 assays for clinical efficacy of atezolizumab in non-small cell
• Waterhouse et al. JClinOncol 2020 — Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer CheckMate
• Kato et al. JImmunotherCancer 2020 — Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with
• Jotte et al. JThoracOncol 2020 — Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131) results from a
• Lantuejoul et al. JThoracOncol 2020 — Interobserver reliability of programmed cell death ligand-1 scoring using the VENTANA PD-L1 (SP263) assay in NSCLC
• Mazieres et al. JThoracOncol 2021 — Atezolizumab versus docetaxel in pretreated patients with NSCLC final results from the randomized phase 2 POPLAR and
• Felip et al. Lancet 2021 — Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010) a
• Goldberg et al. LancetOncol 2020 — Pembrolizumab for management of patients with NSCLC and brain metastases long-term results and biomarker analysis from
• Park et al. LungCancer 2021 — Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in
• Herbst et al. NEnglJMed 2020 — Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC
• Barlesi et al. OncoImmunology 2020 — Effectiveness and safety of nivolumab in the treatment of lung cancer patients in france preliminary results from the

Clinical-NSCLC-EGFR

• Watanabe et al. EurJCancer 2024 — A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC
• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following

Clinical-irAE

• Socinski et al. JAMAOncol 2023 — Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer
• Asao et al. LungCancer 2024 — Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune